Gilead Sciences' Harvoni sales weighed on results, but the company's balance sheet strengthened.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the biggest companies in biopharma, but that hasn't kept investors from selling its shares this year. Stiffening competition in the market for hepatitis C treatment has caused sales of its multibillion-dollar hepatitis C drug Harvoni to falter, and that'...
07:53 EFG International to cut up to 450 jobs as part of BSI integration16
10:05 JPMorgan, HSBC, Credit Agricole Fined $521 Million Over Euribor19
06:10 Sources: Carlos Gomez, Rangers agree on 1-year, $11.5 million deal21
04:16 Red Sox get ace Chris Sale from White Sox for hefty package16